Metal Tiger Drilling commences at Cobre Perrinvale VHMS Project

Cobre Metal Tiger

Metal Tiger plc (LON:MTR), the London Stock Exchange AIM listed investor in natural resource opportunities, has announced that Cobre Limited (ASX:CBE), in which Metal Tiger owns a c.18.8% interest, has today announced that Cobre’s third drilling programme at the Perrinvale VHMS Project has commenced, with the diamond drill (DD) rig now onsite. The reverse circulation drill rig is due to mobilise to site this week.

Highlights:

  • Cobre’s programme includes 6,000m of RC and DD drilling at Perrinvale, with the dual aim of extending current VHMS mineralisation and drill testing new targets.
  • Metallurgical test work will commence on an ore sample from the Schwabe Prospect.

Cobre’s full announcement including maps of prospect locations can be found here:

https://www.asx.com.au/asxpdf/20200610/pdf/44jj6twncch3xp.pdf

As announced on 28 April 2020, Metal Tiger has conditionally agreed to invest a further A$310,000, at Cobre’s IPO price of A$0.20 per share, which will result in the issue of 1,550,000 new Cobre Shares to Metal Tiger. As Metal Tiger is a substantial shareholder in Cobre and has Board representation, the completion of the MTR Investment requires the approval of Cobre shareholders, with such approval to be sought at the Cobre’s Annual General Meeting, to be held later this year. Should shareholders approve the MTR Investment, Metal Tiger will be interested in 20,900,000 Cobre Shares, which, assuming no further shares are issued by Cobre, would result in Metal Tiger’s interest in the company increasing to 19.99%.

Mr Michael McNeilly, Chief Executive Officer of Metal Tiger, said:

We are very excited by the start of this latest drilling campaign by Cobre, which follows on from the significant work which has already been done to demonstrate the potential at Perrinvale and has twin objectives of extending confirmed VHMS mineralisation beyond Schwabe prospect, while also stepping out to test new targets at Perrinvale, in order to explore the broader potential of the licence.”

“We look forward to receiving early visual results before assays and analysis are performed by Cobre’s specialised and experienced VHMS technical team, which are expected to further refine the focus and strategy of the second half of the budgeted drill programme.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:

Latest Company News

Avingtrans reports higher interim profit and strong FY26 visibility

Avingtrans PLC reported flat first-half revenue of £78.1m for the six months to 30 November 2025, with adjusted EBITDA up 10.4% to £9.6m and adjusted profit before tax rising 27.1% to £5.7m.

Robert Crayfourd, CQS Natural Resources: Energy, Metals and Market Rotation

CQS Natural Resources Co-Fund Manager Robert Crayfourd discusses the trust’s objectives, recent performance, and positioning across commodities, with a focus on precious metals, energy markets and nuclear opportunities.

Touchstone posts 2025 reserves update highlighting Central Block integration

Touchstone Exploration Inc. announced its independent 2025 reserves evaluation, showing gross 1P reserves of 27,559 Mboe and 2P reserves of 49,558 Mboe.

Meren Energy achieves 2025 production targets and reduces net debt to $155M

Meren Energy reported average 2025 working interest production of 30,800 boepd and sold 12 cargoes at an average $72.2/bbl. The company delivered $440.7 million in EBITDAX, reduced its RBL by $420 million, and ended the year with net debt of $155.3 million.

Multi asset fund Volta Finance generates strong income as CLO activity accelerates

Volta Finance reported active portfolio management in January, resetting CLOs and deploying €4.5m into new opportunities. The fund generated €20m in interest over six months, with NAV of €256.0m at 31 January 2026.

Verici Dx upgrades genomics infrastructure to support scale

Cloud-enabled analytics are strengthening the company’s ability to process data at scale and support wider clinical adoption.

    Search

    Search